user-generated· regulatory
FDA approves at least one new AstraZeneca blockbuster drug by Q3 2027
Despite the recent trial failure, AstraZeneca’s robust pipeline includes multiple late-stage assets with blockbuster potential. If the company rebounds by securing regulatory approvals, it could restore investor confidence.
regulatory · Prediction Market
- Implied probability (Yes)
- 60%
- Closes
- 2027-09-30
More regulatory markets
- UK government increases teacher pay offer by 2%+ in 2027 — 45% Yes
- FIFA issues formal disciplinary action against Trump by 2026-12-31 — 70% Yes
- UK government to allocate £200M for river clean-up by 2026 — 70% Yes
- FIFA issues formal reprimand against U.S. Soccer for Trump interference — 75% Yes
- Trump administration implements AI guardrails by Q4 2026 — 70% Yes
- FIFA reinstates Balogun suspension within 30 days — 70% Yes
- Mississippi will revoke xAI's turbine loophole by Q4 2026 — 75% Yes
- Forge Global secures Anthropic approval within 6 months — 75% Yes
Loading…